1 - ISGlobal, Barcelona, Spain.
2 - Universitat Pompeu Fabra (UPF), Barcelona, Spain.
3 - CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
4 - IMIM (Hospital del Mar Research Institute), Barcelona, Spain.
5 - CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.
6 - Medida, Lda Porto, Porto, Portugal.
7 - KYomed INNOV, Montpellier, France.
8 - Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium.
9 - MACVIA-France, Montpellier, France.
10 - Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark.
11 - Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia.
12 - Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Research Network, Barcelona, Spain.
13 - ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Salvador, Brazil.
14 - Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, The Netherlands.
15 - Euforea, Brussels, Belgium.
16 - Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium.
17 - Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
18 - Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.
19 - Center for Rhinology and Allergology, Wiesbaden, Germany.
20 - Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.
21 - Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania.
22 - Clinic of Chest diseases and Allergology, Faculty of Medicine, Institute of Clinical Medicine, Vilnius, Lithuania.
23 - Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.
24 - Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden.
25 - Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
26 - Allergy and Clinical Immunology Unit, Department of Medical Sciences, University of Torino & Mauriziano Hospital, Torino, Italy.
27 - Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany.
28 - CRI-Clinical Research International-Ltd, Hamburg, Germany.
29 - Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, University of Barcelona, Barcelona, Spain.
30 - Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.
31 - Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK.
32 - Allergy Department, Pasteur Institute, Paris, France.
33 - Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.
34 - Department of General ORL, H&NS, Medical University of Graz, Graz, Austria.
35 - Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.
36 - Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.
37 - Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.
38 - University Hospital, Montpellier, France.
39 - INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France.
40 - UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Versailles, France.
41 - Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
42 - Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin Institute of Health, Berlin, Germany.
43 - Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität, Marburg, Germany.
Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently.
Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated.
Results: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures.
Conclusions: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.
Palavras Chave: MASK; asthma; rhinitis; score; visual analogue scale.